<DOC>
	<DOC>NCT00631410</DOC>
	<brief_summary>To assess the safety and tolerability of sunitinib when administered in combination with modified FOLFOX6 in Japanese patients with metastatic colorectal cancer in the first-line treatment setting.</brief_summary>
	<brief_title>Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma of the colon or rectum with documented locally advanced or metastatic disease. Evidence of unidimensionally measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Prior treatment with systemic therapy for locally advanced or metastatic colorectal cancer. Prior surgery or investigational agent within 4 weeks prior to study entry. Pregnancy or breastfeeding. All female patients of reproductive potential must have a negative pregnancy test (serum or urine) prior to the start of the study.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>CRC</keyword>
	<keyword>SU011248</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>metastatic carcinoma of the colon or rectum</keyword>
</DOC>